IP Library › Granted Patent US 12,226,521
Granted Patent B2
US 12,226,521 · App. 18/157,302 · Granted Feb 18, 2025

Methods of intravenous administration of glyburide

Inventor: Sven Martin Jacobson (New York, NY)
Assignee: REMEDY PHARMACEUTICALS, INC.
A61K9/0019A61K31/17A61K31/18A61K31/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,521
App. No.
18/157,302
Granted
Feb 18, 2025
Kind
B2
Abstract

The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

Claims (26)

1. A method of administering glyburide to a subject, comprising:

(a) a first bolus administration of glyburide;

(b) a first continuous infusion administration of glyburide after the first bolus administration of glyburide, wherein the first continuous infusion glyburide is administered at a first rate of administration for a first period of time; and

(c) a second continuous infusion administration of glyburide after the first continuous infusion of glyburide wherein in the second continuous infusion glyburide is administered at a second rate of administration for a second period of time;

wherein the glyburide is administered to the subject over a period of time, and

wherein the subject is in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia.

2. The method of claim 1 , wherein the first and second rate of administrations are each about 15 μg/hr and about 300 μg/hr.

3. The method of claim 1 , wherein the total amount of glyburide administered during administration is less than about 10 mg per day.

4. The method of claim 1 , wherein the total amount of glyburide administered during administration is less than about 6 mg per day.

5. The method of claim 1 , wherein the total amount of glyburide administered during administration is less than about 3.5 mg per day.

6. The method of claim 1 , wherein the total amount of glyburide administered during administration is less than about 3 mg per day.

7. The method of claim 1 , wherein the first rate of administration is greater than the second rate of administration.

8. The method of claim 7 , wherein the first period of time is about 1 hour to about 10 hours.

9. The method of claim 8 , wherein the second period of time is a period of time of about 1 hour to about 10 hours.

10. The method of claim 1 , wherein the method is used to treat acute stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, hypoxia/ischemia, or other injuries, conditions, and disorders.

11. The method of claim 1 , wherein the first continuous infusion has a rate of about 150 μg/hr to about 175 μg/hr of glyburide for a period of time of about 6 hours.

12. The method of claim 11 , wherein the second continuous infusion has a rate of about 100 μg/hr to about 125 μg/hr glyburide.

13. The method of claim 12 , wherein the second continuous infusion is administered over a period of time of about 66 hours, and where the sum of the first continuous infusion and of the second continuous infusion total a period of time of about 72 hours.

14. The method of claim 1 , wherein the first bolus administration delivers about 125 μg to about 150 μg glyburide.

15. The method of claim 1 , wherein the second bolus administration delivers about 125 μg to about 150 μg glyburide.

16. The method of claim 1 , wherein the first continuous infusion administration has a rate of about 15 μg/hr to about 300 μg/hr glyburide.

17. The method of claim 1 , wherein the second continuous infusion administration has a rate of about 15 μg/hr to about 300 μg/hr glyburide.

18. The method of claim 1 , wherein the first bolus administration comprises administration of about 130 μg of glyburide followed by the first infusion of about 163 μg/hr glyburide for 6 hours followed by the second infusion of about 112 μg/hr glyburide for 66 hours.

19. The method of claim 1 , further comprising:

(d) a third continuous infusion administration of glyburide, after the second continuous infusion of glyburide wherein the third continuous infusion of glyburide is administered at a third rate of administration for a third period of time.

20. The method of claim 19 , wherein the period of time is about 1 hour to about 72 hours.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2023
From: BIOGEN CHESAPEAKE LLC
To: REMEDY PHARMACEUTICALS, INC.
Reel/Frame 064678/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2023
From: REMEDY PHARMACEUTICALS, INC.
To: BIOGEN CHESAPEAKE LLC
Reel/Frame 063861/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2023
From: JACOBSON, SVEN MARTIN
To: REMEDY PHARMACEUTICALS, INC.
Reel/Frame 063861/0466 →
Continuity (10)
Continuation 17030925 · Sep 24, 2020
Continuation 16459893 · Jul 2, 2019
Continuation 15686989 · Aug 25, 2017
Continuation 15425874 · Feb 6, 2017
Continuation 15422358 · Feb 1, 2017
Continuation 14878232 · Oct 8, 2015
Continuation 14525992 · Oct 28, 2014
Continuation 13811037
Provisional Application 61365689 · Jul 19, 2010
Related Publication 20230414489A1 · Dec 28, 2023
References Cited (82)
US 7285574B2 · Simard et al. · 2007 [cited by applicant]
US 7872048B2 · Simard · 2011 [cited by applicant]
US 8136330B2 · Ostler · 2012 [cited by applicant]
US 20040073192A1 · Flament-Garcia · 2004 [cited by applicant]
US 20050148928A1 · Molina · 2005 [cited by applicant]
US 20080220441A1 · Birnbaum et al. · 2008 [cited by applicant]
US 20090233995A1 · Lautt · 2009 [cited by applicant]
CN 1960735A · 2007 [cited by applicant]
EP 2595633A2 · 2013 [cited by applicant]
JP 2000512266A · 2000 [cited by applicant]
WO 2005112949A1 · 2005 [cited by applicant]
WO 2006036278A2 · 2006 [cited by applicant]
WO 2008038126A2 · 2008 [cited by applicant]
WO 2009002832A2 · 2008 [cited by applicant]
WO 2009097443A2 · 2009 [cited by applicant]
WO 2012012347A2 · 2012 [cited by applicant]
Garrell et al.; Acute Effect of Glyburide on Insulin Sensitivity in Type I Diabetic Patients; Journal of Clinical Endocrinology and Metabolism; Nov. 1, 1987; pp. 896-900; vol. 65, No. 5; The Endocrine Society; US. [cited by applicant]
Jonsson et al.; Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes; European Journal of Clinical Pharmacology; Dec. 1, 2000; pp. 711-714; vol. 56, No.… [cited by applicant]
Jonsson et al.; Pharmacodynamics and pharmacokinetics of intravenous glibenclimide in Caucasian and Chinese patients with type-2 diabetes; European Journal of Clinical Pharmacology; Jan. 1, 2000; pp. 721-727; vol. 55, N… [cited by applicant]
Rogers, et al.; Pharmacokinetics of Intravenous Glibenclamide Investigated by a High Performance Liquid Chromatographic Assay; Diabetologia; Jul. 1, 1982; pp. 37-40; vol. 23, No. I; Springer-Verlag, Berlin, Germany. [cited by applicant]
Rydberg et al.; Concentration-effect relations of glibenclamide and its active metabolites in man: modeling of Pharmacokinetics and Pharmacodynamics; British Journal of Clinical Pharmacology; Apr. 1, 1997; pp. 373-373; … [cited by applicant]
Sorgel et al.; Pharmacodynamics of oral and parenteral Glibenclamide; Pharmaceutical Research (supplement); Nov. 1997; pp. SI 77-SI 78; vol. 14, No. 11; (also from Annual Meeting of the American Association of Pharmaceu… [cited by applicant]
Bank et al, “Vascular ATP-dependent potassium channels, nitric oxide, and human forearm reactive hyperemia.” Cardiovasc. Drugs Ther., 2000, 14(1):23-29. [cited by applicant]
Bauerafelnd et al, “Comparative Bactericidal Effect of Discontinuous vs Continuous Dosing of Meropenem in a Pharmacodynamic Model”, Pharmaceutical Research, 1997, pp. 3, vol. 14, No. 11, New York. [cited by applicant]
Billman et al, “The Effects of the ATP-Dependent Potassium Channel Antagonist, Glyburide, on Coronary Blood Flow and Susceptibility to Ventricular Fibrillation in Unanesthetized Dogs”, Journal of Cardiovascular Pharmaco… [cited by applicant]
Boggs et al, “Potential of Glyburide to Reduce Intracerebral Edema in Brain Metastases”, Expert Reviews, 2014, pp. 10, vol. 14, Issue 4, Baltimore, MD. [cited by applicant]
Britton et al, “Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors an Glycaemic Control in Patients with Type 2 Diabetes Mellitus”, Clinical Pharmacodynamics, 1998, pp. 17, London, England. [cited by applicant]
Chatila et al, “Hepatomegaly and abnormal liver tests due to glycogenosis in adults with diabetes.” Medicine (Baltimore), 75:327-333, 1996. [cited by applicant]
El-Reyani et al, “Comparison of the Efficacy of Glibenclamide and Glimepiride in Reperfusion-Induced Arrhythmias In Rats”, European Journal of Pharmacology, 1999, pp. 187-192, vol. 365, Hungary. [cited by applicant]
Elrod et al, “Role of Sulfonylurea Receptor Type 1 Subunits of ATP-Sensitive Potassium Channels in Myocardial Ischemia/Reperfusion Injury”, Circulation Journal of the AHA, Mar. 2008, pp. 10, Online ISSN 1524-4539, Dalla… [cited by applicant]
Figura et al, “Blockade of KATP Channels Reduces Enothelial Hyperpolarization and Leukocyte Recruitment Upon Reperfusion After Hypoxia”, American Journal of Transplantation, 2009, pp. 687-696, vol. 9, Alberta, Canada. [cited by applicant]
Zhou et al, “Glibenclamide Improves Neurological Function in Neonatal Hypoxia Ischemia in Rats”, Brain Research, Mar. 2009, pp. 33, Loma Linda, CA. [cited by applicant]
Groop et al, “Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects.”, Diabet, 1987, 36:1320-1328. [cited by applicant]
Groop et al, “Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans.” Diabetes Care. Aug. 1991;14(8):724-7. [cited by applicant]
Irwin et al, “Dietary wheat starch and sucrose: Effects on levels of5 enzymes in the blood serum of young adults.” Am J Clin Nutr 22, 701-9, 1969. [cited by applicant]
Iskit et al, “Glibenclamide Attenuates the Antiarrhythmic Effect ofEndotoxin with a Mechanism not Involving KATP Channels”, ScienceDirect, 2006, pp. 129-136, Turkey. [cited by applicant]
Jayakumar et al, “Sulfonylurea Receptor 1 Contributes to the Astrocyte Swelling and Brain Edema in Acute Liver Failure”, Springer Science, Jan. 2014, pp. 10, New York. [cited by applicant]
Jew et al, “Glibenclamide Improves Postischemic Recovery of Myocardial Contractile Function in Trained and Sedentary Rats”, University of Colorado Cardiovascular Institute, May 2001, pp. 10, Boulder, CO. [cited by applicant]
Vajda et al, “Selective Cardiac Plasma-Membrane KATP, Channel Inhibition is Defibrillatory and Improves Survival During Acute Myocardial Ischemia and Reperfusion”, European Journal of Pharmacology, 2007, pp. 115-123, vo… [cited by applicant]
Szabo et al, “Inhibition of ATP-Activated Potassium Channels Exerts Pressor Effects and Improves Survival in a Rat Model of Severe Hemorrhagic Shock”, Shock: Rapid Communication, 1996, pp. 391-394, vol. 5 No. 6, Cincinn… [cited by applicant]
Katoh et al, “Association Between Body Composition and Glucose Intolerance in Patients with Quadriplegics”, Sogo Rehabilitation, Apr. 2003, vol. 31, No. 4, Japan. [cited by applicant]
Kechagieas et al, “Fast food based hyper-alimentation can induce rapid and profound elevation in serum alanine aminotransferase in healthy subjects”, Gut 57(5):649-54, 2008. [cited by applicant]
Office Action for Japanese application No. 2013-520785, dated Apr. 22, 2015. [cited by applicant]
Legtenberg et al, “Glibenclamide Attenuates Ischemia-Induced Acidosis and Loss of Cardiac Function In Rats”, European Journal of Pharmacology, 2002, pp. 35-42, vol. 434, Netherlands. [cited by applicant]
Maekawa et al, “Clinical Image of Acute Myocardial Infraction as a Complication of Diabetes—Study With Respect to the Presence of Glibenclamide Dosing”, Japanese Circulation Journal, Sep. 2000, pp. 2, vol. 64, Japanese … [cited by applicant]
Mahgoub et al, “Diabetes Mellitus and Cardiac Function”, Molecular and Cellular Biochemisrty, 1998, pp. 59-64, vol. 180, Richmond, VA. [cited by applicant]
Maybauer et al, “The ATP-Sensitive Potassium-Channel Inhibitor Glibenclamide Improves Outcome in an Ovine Model of Hemorrhagic Shock”, University of Texas Medical Branch, Jul. 2004, pp. 387-391, vol. 22, No. 4, Texas. [cited by applicant]
Mcewen et al, “Characterisation of glibenclamide half-life in man: acute concentration-effect relationships”, Clinical Science, 1982, 63:28. [cited by applicant]
Morrison et al, “Effect of pirprofen on glibenclamide kinetics and response”, Br. J. Clin. Pharmac, 1982, 14:123-126. [cited by applicant]
Neugebauer et al, “Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N)”, Int. J. Clin. Pharmacol. Ther. Toxicol, 1985, 23(9):453-60. [cited by applicant]
Oku, “Arterioslerotic Disease Management of Disease as a Complication in Stroke Rehabilitation”, Gendai Iryo, Up Date, 1992, pp. 14, vol. 92, No. 24, ISSN 0533-7259, Japan. [cited by applicant]
Patel et al, “Glibenclamide Reduces Hippocampal Injury and Preserves Rapid patial Learning in a Model of Traumatic Brain Injury”, J Neuropathol Exp Neurol, ecember 2010, pp. 1177-1190, vol. 69, No. 12, Maryland. [cited by applicant]
Pompermayer et al, “Effects of the Treatment with Glibenclamide, an ATP- Sensitive Potassium Channel Blocker, on Intestinal Ischemia and Reperfusion Injury”, European Journal of Pharmacology, 2007, pp. 215-222, vol. 556… [cited by applicant]
Pompermayer et al, “The ATP-Sensitive Potassium Channel Blocker Glibenclamide Prevents Renal Ischemia/Reperfusion Injury in Rats”, Kidney International, 2005, pp. 1785-1796, vol. 67, Brazil. [cited by applicant]
Porikos et al, “Diet induced changes in serum transaminase and triglyceride levels in healthy adult men”, Am J Med, 75:624-30, 1983. [cited by applicant]
Purkins et al, “The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase 1 unit”, British Journal of Clinical Pharmacology 57:2, 199-208, 2003. [cited by applicant]
Rogers et al, “Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay”, Diabet, 1982, 23:37-40. [cited by applicant]
Rydberg et al, “Comparison of the kinetics of glyburide and its active metabolites in humans”, J. Clin. Pharm. Ther, 1995, 20(5):283-295. [cited by applicant]
Rydberg et al, “Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans”, Diabet. Care, 1994, 17:1026-103. [cited by applicant]
Sayuk et al, “Hepatic glycogenosis: An under-recognized source for abnormal liver function tests”, Dig Dis Sci., 52:936-938, 2007. [cited by applicant]
Simard et al, “Endothelial Sulfonylurea Receptor 1- Regulated NCCa-ATP Channels Mediate Progressive Hemorrhagic Necrosis Following Spinal Cord Injury”, Journal of Clinical Investigation, May 2007, pp. 9, Baltimore, MD. [cited by applicant]
Simard et al, “Glibenclamide is Superior to Decompressive Craniectomy in a Rat Model ofMilignant Stroke *Online-Only Data Supplement (Methods)”, Stroke: Journal of the AHA, 2010, pp. 10, ISSN: 1524-4628, Dallas, TX. [cited by applicant]
Simard et al, “Key Role of Sulfonylurea Receptor 1 in Progressive Secondary Hemorrhage Following Brain Contusion”, Journal ofNeurotrauma, 2009, pp. 42, New Rochelle, NY. [cited by applicant]
Simard et al, “Newly Expressed SURI-Regulated NCCa-ATP Channel Mediates Cerebral Edema After Ischemic Stroke”, Nature Medicine, Apr. 2006, pp. 433-440, vol. 12, No. 4, Baltimore MD. [cited by applicant]
Simard et al, “Protective Effect of Delayed Treatment with Low-Dose Glibenclamide in Three Models oflschemic Stroke *Supplemental Methods”, Stroke: Journal of the AHA, 2009, pp. 8, ISSN: 1524-4628, Dallas, TX. [cited by applicant]
D'Arcy, PF (Ed): “Drug interactions with medical plastics”, Drug Intelligence and Clinical Phar, Cincinnati, Oh, US, vol. 17, No. 10, 1983, pp. 726-731. [cited by applicant]
Fukazawa, T., et al: Reduction of non-specific adsorption of drugs to plastic containers used In bioassays or analyses 11, Journal of Pharmacological and Toxicological Methods., vol. 61, No. 3, 2010,pp. 329-333. [cited by applicant]
De Muynck, C., et al: “Binding of Drugs To End-Line Filters: a Study of Four Commonly Administered Drugs in Intensive Care Units”, Journal of Clinical Pharmacy and Therapeutics., vol. 13, No. 5., 1988, pp. 335-340. [cited by applicant]
Weltje, L., et al: “Adsorption of metals to membrane filters in view of their speciation in nutrient solution”, Environmental Toxicology and Chemistry., vol. 22. No. 2., 2003, pp. 265-271. [cited by applicant]
Breme, F., et al: Coating of polymers with titanium-based layers by a novel plasma-assisted chemical vapor deposition process 11, Thin Solid F, Elsevier, Amsterdam, NL, vol. 377-378, 2000, pp. 755-759. [cited by applicant]
Anonymous: 11 Alternatives to PVC for IV bags : Packaging Digest 11, 2002, XP055468910, Retrieved from the Internet: URL:http://www.packagingdigest.com/drug-delivery/pmp-alternatives-pvc-iv-bags-020417. [cited by applicant]
Panten, U., et al: 11 Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochemical Pharmacology. Elsevier. US, vol.… [cited by applicant]
Extended European Search Report dated May 18, 2018 cited in European Application No. 18157269.4, 11 pages. [cited by applicant]
Translation of Notice of Reasons for Rejection mailed Jun. 11, 2018 in JP2017-51153, 7 pages. [cited by applicant]
Sorgel et al, “New Investigation of glibenclamide's bioavailability”, Pharm. Res, 1997, 14:S251. [cited by applicant]
Spraul et al, “Uniform elimination pattern for glibenclamide in healthy Caucasian males”, Arzneimittelforschung, 1989, 39(11):1449-1450. [cited by applicant]
Grover et al., The J. of Pharmacology and Experimental Therapeutics, 297 (3), pp. 1184-1192. [cited by applicant]
Chen et al. “Impact of Infusion Apparatus on Clinical Medication Safety”, China Pharmacy, 2007, vol. 18, No. 26, pp. 2073-2075 (Partial Translation). [cited by applicant]
Notice of Preliminary Rejection cited in Korean Application No. 10-2018-7032015 dated Aug. 26, 2019, with an English translation, 12 pages. [cited by applicant]
Notice of Reasons for Rejection cited in Japanese Patent Application No. 2018-230763 dated Sep. 20, 2019 with a English translation, 16 pages. [cited by applicant]
Lee, “Sorption of four drugs to polyvinyrchloride and polybutadiene intravenous administration sets”, American Journal of Hospital Pharmacy, vol. 43, Aug. 1986, pp. 1945-1950. [cited by applicant]
Pearson, J.G., “Pharmacokinetics of Glyburide”, The American Journal of Medicine, vol. 79, (suppl 3B), Sep. 1985, pp. 67-71. [cited by applicant]